Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib
BiotechTV - News
00:00
Timing and plans for 90‑day cohort data
Richard confirms collection of 90-day data and upcoming abstracts for AAD and SID meetings.
Play episode from 12:04
Transcript
